Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade

Group 1 - BofA Securities has upgraded Inspire Medical Systems from Neutral to Buy, indicating the company is now categorized under profitable growth [1][3][6] - Inspire Medical is expected to provide its 2025 revenue guidance in early January, aligning with its fourth-quarter results, and is comfortable with the consensus of $950 million in revenue for 2025 [1][3] - For 2024, Inspire Medical anticipates sales between $793 million and $798 million, slightly above prior guidance and in line with consensus estimates [2] Group 2 - The company's growth outlook for 2025 includes plans to hire more staff, open new centers, increase direct-to-consumer advertising, expand treatment indications, and enhance capacity [3] - The Inspire V system, approved by the FDA, is expected to simplify procedures and increase accessibility for various types of surgeons, with a soft launch planned for late 2024 and a full launch in 2025 [4][5] - The analyst notes that Inspire Medical is positioned as an attractive smid cap growth stock with potential for double-digit margins, which could lead to increased strategic interest [6]